Cigna
CI
Market cap $81B

303.27 USD

-5.51

1.78%

At close Jul 11, 4:00 PM EDT

After hours

303.27

+0.00

0.00%

1 day

-1.78%

5 days

-5.50%

1 month

-2.23%

3 months

-8.15%

6 months

7.37%

Year to date

10.48%

1 year

-9.08%

5 years

70.98%

10 years

95.59%

About: Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM and specialty pharmacy services, which were greatly expanded by its 2018 merger with Express Scripts, are mostly sold to health insurance plans and employers. Its largest PBM contract is with the Department of Defense (current contract through 2029), and it recently won a multiyear deal with top-tier insurer Centene. In health insurance and other benefits, Cigna primarily serves employers through self-funding arrangements, and the company operates mostly in the US with 17 million US and 2 million international medical members covered as of December 2024.

Employees: 73,500

Healthcare Healthcare Plans

0

Funds holding %

of 7,312 funds

0

Analysts bullish %

of 8 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

73% more funds holding in top 10

Funds holding in top 10: 22 [Q4 2024] → 38 (+16) [Q1 2025]

60% more call options, than puts

Call options by funds: $1.41B | Put options by funds: $879M

50% more first-time investments, than exits

New positions opened: 195 | Existing positions closed: 130

16% more capital invested

Capital invested by funds: $67.1B [Q4 2024] → $77.9B (+$10.9B) [Q1 2025]

3% more funds holding

Funds holding: 1,617 [Q4 2024] → 1,658 (+41) [Q1 2025]

0.04% more ownership

Funds ownership: 87.36% [Q4 2024] → 87.4% (+0.04%) [Q1 2025]

8% less repeat investments, than reductions

Existing positions increased: 571 | Existing positions reduced: 623

See Fund Rankings

Research analyst outlook

8 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$362

19%

upside

Avg. target

$383

26%

upside

High target

$405

34%

upside

8 analyst ratings

8 positive

100%

0 neutral

0%

0 negative

0%

RBC Capital Ben Hendrix	22%upside $371	Outperform Reiterated	26 Jun 2025
Barclays Andrew Mok	27%upside $385	Overweight Maintained	2 Jun 2025
Guggenheim Jason Cassorla	28%upside $388	Buy Reiterated	23 May 2025
Truist Securities David Macdonald	34%upside $405	Buy Maintained	12 May 2025
Piper Sandler Jessica Tassan	23%upside $374	Overweight Maintained	5 May 2025

See Analyst Rankings

Financial journalist opinion

Based on 13 articles about CI published over the past 30 days

Cigna: Price Pullback Is A Great Opportunity

Cigna trades at a significant discount to the S&P 500, offering a higher yield and faster dividend growth, making it attractive for total return investors. CI's robust earnings growth is fueled by its Evernorth and Healthcare segments, with strong results and promising exposure to the booming GLP-1 drug market. Management targets 10-14% annual EPS growth, supported by aggressive share buybacks and a safe, growing dividend nearly double the S&P 500 yield.

Cigna: Price Pullback Is A Great Opportunity

Don't Miss Out On These 3 Dirt-Cheap SWANs

We prefer to buy and hold stocks with a significant margin of safety. Today, we're highlighting a global tech and e-commerce juggernaut, the leading life sciences REIT, and a major managed healthcare and insurance company. The stocks are priced 20% to 38% below our fair value estimates.

Don't Miss Out On These 3 Dirt-Cheap SWANs

Zacks Investment Research

UnitedHealth vs. Cigna: Which Insurer to Buy Amid Sector Turmoil?

CI's commercial focus and clearer outlook set it apart as UNH faces guidance pulls, CEO change and rising medical costs.

UnitedHealth vs. Cigna: Which Insurer to Buy Amid Sector Turmoil?

The Cigna Group Foundation Addresses Mental Health and Housing Stability for Veterans with $3 Million in Grants

Nonprofits are encouraged to apply now for 2025 funding The Cigna Group Foundation committed $9 million in 2024 to address veteran mental health, distributing $3 million each year through 2026 In first year, 23 grantees were awarded grants to help local veterans feel stable where they live, create positive impact on their mental health BLOOMFIELD, Conn. , July 8, 2025 /PRNewswire/ -- The Cigna Group Foundation, the philanthropic arm of The Cigna Group (NYSE: CI), announced today a new round of grants aimed at improving the mental health of military veterans.

The Cigna Group Foundation Addresses Mental Health and Housing Stability for Veterans with $3 Million in Grants

Zacks Investment Research

Cigna Expands Coverage With RhinAer & Enhances Rhinitis Treatment

CI to cover RhinAer for chronic rhinitis starting Sept. 15, expanding access to a minimally invasive, office-based treatment.

Cigna Expands Coverage With RhinAer & Enhances Rhinitis Treatment

The Cigna Group Foundation Announces Grants to 24 Nonprofits, Builds on Momentum to Help Address Youth Mental Health Crisis

BLOOMFIELD, Conn. , June 30, 2025 /PRNewswire/ -- The Cigna Group Foundation, the philanthropic arm of The Cigna Group (NYSE: CI), today announced its second round of grant recipients supporting youth mental health.

The Cigna Group Foundation Announces Grants to 24 Nonprofits, Builds on Momentum to Help Address Youth Mental Health Crisis

Cigna Enables Coverage for RhinAer®

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aerin Medical Inc., a leader in minimally invasive solutions for chronic nasal conditions, today announced that Cigna Healthcare will provide coverage for RhinAer® treatment of the posterior nasal nerve (CPT 31242), effective September 15, 2025. This change removes RhinAer from Cigna's list of procedures deemed experimental, investigational, and unproven, marking a significant step forward in expanding access to a best-in-class treatment option for patien.

Cigna Enables Coverage for RhinAer®

Zacks Investment Research

4 HMO Stocks Set to Thrive From Steady Premium Flows, M&A Strategy

Rising premiums, ongoing technological innovation and the growing demand for Medicare plans are anticipated to propel the performance of the Zacks Medical-HMO industry players. CI, HUM, CNC and MOH are poised to benefit from favorable industry prospects.

4 HMO Stocks Set to Thrive From Steady Premium Flows, M&A Strategy

The Cigna Group's Second Quarter 2025 Earnings Release Details

BLOOMFIELD, Conn. , June 25, 2025 /PRNewswire/ -- Global health company The Cigna Group (NYSE: CI) will release its second quarter 2025 financial results on Thursday, July 31, 2025, and will host a conference call the same day.

The Cigna Group's Second Quarter 2025 Earnings Release Details

Cigna sues Bristol Myers over alleged monopoly for multiple myeloma drug Pomalyst

Cigna sued Bristol Myers on Tuesday, accusing the drugmaker of violating federal antitrust law by maintaining a monopoly over a blockbuster multiple myeloma drug sold under the brand name Pomalyst.

Cigna sues Bristol Myers over alleged monopoly for multiple myeloma drug Pomalyst

See News Rankings

Charts implemented using Lightweight Charts™